- |||||||||| Cytovene (ganciclovir) / Roche, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Post Transplant Lymphoproliferative Disorder Masquerading as a Lung Mass After Lung Transplantation (Area D, Hall F (North Building, Exhibition Level), Moscone Center) - Feb 19, 2022 - Abstract #ATS2022ATS_3315;
Prevention usually relies upon limiting aggressive immunosuppressive regimens; however more recent studies have shown antiviral prophylaxis such as ganciclovir or acyclovir may play a role in reducing risk...[2] The overall incidence of PTLD is approximately 1 percent in the transplant population with the lowest rate among hematopoietic stem cell transplant, renal, and liver transplants and highest among intestinal and multiorgan transplants. [3] While uncommon, PTLD is important to recognize given the serious and potentially fatal complications that can arise when it is untreated.
- |||||||||| Zirgan (ganciclovir ophthalmic gel) / Bausch Health, Thea Laboratories, Cytovene (ganciclovir) / Roche
A Case of Necrotizing Sarcoid Granulomatosis (Area I, Hall F (North Building, Exhibition Level), Moscone Center) - Feb 19, 2022 - Abstract #ATS2022ATS_2555;
NSG’s definite diagnosis requires excluding a malignant, infectious, or autoimmune process that may also present with granuloma. NSG holds a favorable prognosis with a good response to steroid treatment
- |||||||||| Cytovene (ganciclovir) / Roche, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Consider This Cause of Critical Illness: Kaposi Sarcoma Inflammatory Cytokine Syndrome (Room 3009/3011 (West Building, Level 3), Moscone Center) - Feb 19, 2022 - Abstract #ATS2022ATS_2035;
The possibility of IRIS was raised given the proximity of the patient’s decompensation to initiation of anti-retroviral therapy, but ultimately it seemed too soon for immune reconstitution. The optimal treatment of KICS is not entirely clear; management strategies have included chemotherapy and anti-viral therapy. Kaposi sarcoma inflammatory syndrome causes critical illness, and clinicians must maintain a high index of suspicion for this lesser-known entity given its high mortality.
- |||||||||| Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche
Cytomegalovirus (CMV) Reactivation in COVID 19: A Case Series (Area J, Hall F (North Building, Exhibition Level), Moscone Center) - Feb 19, 2022 - Abstract #ATS2022ATS_1281;
An association between CMV reactivation and COVID 19 has been documented but we need further research on a cause effect relationship and immunopathology in such cohorts. It would be worthwhile to probe an association of quantum of immunological response along with viral loads in a coinfection with COVID 19 and CMV in such cohorts more so when it becomes difficult to differentiate between COVID 19 and CMV pneumonias clinically.
- |||||||||| Cytovene (ganciclovir) / Roche
Journal: Choroidal Involvement in a Case of Acute Retinal Necrosis. (Pubmed Central) - Feb 17, 2022
The final visual acuity post silicone oil removal was 6/60. This is a unique case of ARN having choroidal involvement along with the previously described classical features.
- |||||||||| Vistide (cidofovir) / Gilead
Review, Journal: Tribute to John C. Martin at the Twentieth Anniversary of the Breakthrough of Tenofovir in the Treatment of HIV Infections. (Pubmed Central) - Feb 15, 2022
At Gilead, John succeeded in obtaining the approval from the US FDA for the use of cidofovir in the treatment of cytomegalovirus (CMV) retinitis in AIDS patients, which was reminiscent of John's first experience with ganciclovir (at Syntex) as an anti-CMV agent. At Gilead, John would then engineer the development of tenofovir, first as TDF (tenofovir disoproxil fumarate) and then as TAF (tenofovir alafenamide) and various combinations thereof, for the treatment of HIV infections (i), TDF and TAF for the treatment of hepatitis B (HBV) infections (ii), and TDF and TAF in combination with emtricitabine for the prophylaxis of HIV infections (iii).
- |||||||||| Cytovene (ganciclovir) / Roche
CHROMOSOMALLY INTEGRATED HHV-6 IN AN ASYMPTOMATIC NEONATE. (E-Poster Stations) - Feb 10, 2022 - Abstract #ESPID2022ESPID_53;
PCR in plasma and whole blood were also both positive (2530 cp/ml and 2.200.000 cp/ml respectively) for HHV6 A. Ganciclovir IV was initially started and a second spinal tab was performed during treatment...In follow up viral load was still high, (over 500.000 cp/ml) and antiHHV6 IgG was positive. Learning Points/ Since ciHHV6 is not commonly diagnosed especially in immunocompetent pediatric patients, we think that it is important to get familiar with this rare entity, in order to avoid misdiagnosis and unnecessary treatment, while long term follow up might be needed.
- |||||||||| thioguanine / Generic mfg.
Journal: 6-Thioguanine Inhibits Herpes Simplex Virus 1 Infection of Eyes. (Pubmed Central) - Feb 9, 2022
In addition, we also documented that Rac1 is highly expressed in corneal tissues from HSK patients, indicating that Rac1 is associated with HSK pathogenesis. In view of the high potency of 6-TG, low cytotoxicity, targeting a distinct therapeutic target, we suggest that 6-TG is a potential candidate for development as a therapeutic agent for HSK therapy.
- |||||||||| Cytovene (ganciclovir) / Roche
Journal: Cytomegalovirus pneumonitis amid COVID-19 chaos: the hidden enemy-a case report. (Pubmed Central) - Feb 8, 2022
Among various immunosuppressive therapies that has been tried for cytokine storm, use of anti-interleukin-6 inhibitors in the aforementioned population may carry more harm than previously thought, which may suggest that is reasonable to omit its use in treating this group with coronavirus disease 2019. This case underlines an underrecognized and underreported cause of morbidity and mortality during the course of severe coronavirus disease 2019 and will help to alert clinicians of its occurrence.
- |||||||||| Cytovene (ganciclovir) / Roche
Preclinical, Journal: Evaluating a Targeted Cancer Therapy Approach Mediated by RNA trans-Splicing In Vitro and in a Xenograft Model for Epidermolysis Bullosa-Associated Skin Cancer. (Pubmed Central) - Feb 5, 2022
Notably, a previously established RNA trans-splicing molecule (RTM44) showed efficacy and specificity in exchanging the coding sequence of a cancer target gene (Ct-SLCO1B3) with the suicide gene HSV1-thymidine kinase in a colorectal cancer model, thereby rendering tumor cells sensitive to the prodrug ganciclovir (GCV)...Importantly, systemic GCV treatment of mice bearing RTM44-expressing cancer cells resulted in a significant reduction in tumor volume and weight compared with controls. Thus, our results demonstrate the applicability of RTM44-mediated targeting of the cancer gene Ct-SLCO1B3 in a different malignancy.
- |||||||||| Cytovene (ganciclovir) / Roche
Journal: Progressive, Long-Term Hearing Loss in Congenital CMV Disease After Ganciclovir Therapy. (Pubmed Central) - Feb 1, 2022
In this study, most patients with symptomatic congenital CMV disease and congenital or early-onset SNHL eventually developed hearing loss severe enough to have been potential candidates for cochlear implantation, with or without 6-week ganciclovir therapy. Understanding long-term hearing outcomes of patients treated with 6-month oral valganciclovir (current standard of care) is needed.
- |||||||||| Prevymis (letermovir) / Merck (MSD)
OFF-LABEL USE OF LETERMOVIR IN A PEDIATRIC COHORT OF PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ePoster Area [VIRTUAL]) - Jan 30, 2022 - Abstract #EBMT2022EBMT_1521;
With the limit of sample size, Letermovir seems safe and effective in all indications tested in our pediatric cohort.More studies are needed to address precisely the duration of primary and secondary prophylaxis, considering type of transplantation (e.g. T-depleted), immune reconstitution and any concomitant immunosuppression (GVHD prophylaxis and therapy). Preliminary results with Letermovir as third-line therapy for treatment-refractory CMV-reactivation show clinical efficacy which could be assessed in larger trials.
- |||||||||| Prevymis (letermovir) / Merck (MSD), Cytovene (ganciclovir) / Roche
CYTOMEGALOVIRUS REACTIVATION UNDER PRE-EMPTIVE THERAPY DURING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT: THE PATTERN, SURVIVAL, AND RISK FACTORS IN SOUTH KOREA (ePoster Area [VIRTUAL]) - Jan 30, 2022 - Abstract #EBMT2022EBMT_1515;
Recently, letermovir has been considered as primary prophylaxis for CMV in CMV-seropositive recipients of allogeneic hematopoietic stem cell transplant (HSCT)...CMV monitoring was performed in all enrolled patients using CMV antigen (from 2003 to 2013) or CMV polymerase chain reaction (PCR) (from 2013 to 2020), and pre-emptive therapy for CMV was done using ganciclovir (5 mg/kg, intravenous injection every 12 hours) in the patients who presented CMV antigenemia or PCR titer more than 1,000 copies/ml... In this study, half of the patients with HSCT were treated with pre-emptive therapy for CMV, without any effect on their survival, reflecting that pre-emptive therapy has enough advantage even in CMV endemic area. However, 50% of the patients experienced CMV reactivation repeatedly with a median duration of 14 days more than twice; therefore, it is necessary to re-evaluate the cost-effectiveness of CMV prophylaxis in high-risk patients.
- |||||||||| Cytovene (ganciclovir) / Roche
INCIDENCE AND OUTCOME OF CMV REACTIVATION IN NON-MALIGNANT PEDIATRIC HSCT RECIPIENTS (ePoster Area [VIRTUAL]) - Jan 30, 2022 - Abstract #EBMT2022EBMT_1494;
It correlates with a significantly longer hospital stay, affecting the patients’ quality of life in early stage post-HSCT. Patients presenting with high CMV viremia, developing Ganciclovir resistance, or experiencing multiple reactivations had significantly lower chances for survival.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
CYTOMEGALOVIRUS IMPACT IN B-CELL LYMPHOMA PATIENTS TREATED WITH CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY (ePoster Area [VIRTUAL]) - Jan 30, 2022 - Abstract #EBMT2022EBMT_1197;
CMV monitoring can be useful during the first 2 months after CAR T-cell therapy, especially in those receiving dexamethasone and/or tocilizumab. CMV replication has doubtful clinical significance in this setting, so treatment should be carefully individualized assessing risk-benefit in terms of toxicity.
- |||||||||| Campath (alemtuzumab) / Sanofi, Cytovene (ganciclovir) / Roche
THE SAFETY, FEASIBILITY, AND EFFICACY OF GANCICLOVIR PROPHYLAXIS THROUGH DAY +100 IN PEDIATRIC ALLOSCT RECIPIENTS: BONE MARROW SUPPRESSION SECONDARY TO GANCICLOVIR MAY LIMIT EFFECTIVENESS (Panorama / Virtual Hall 3) - Jan 30, 2022 - Abstract #EBMT2022EBMT_767;
A cox regression univariate analysis was performed for the following risk factors: donor source, sex, malignant disease, disease risk index, conditioning intensity, receipt of rATG/alemtuzumab, GVHD prophylaxis, Grade II-IV GVHD, CMV D/R status, Grade III-IV neutropenia requiring discontinuation of ganciclovir, and CMV viremia... One-year survival was significantly decreased and 1-year NRM was significantly increased in patients who had grade III/IV neutropenia probably or directly attributed to ganciclovir that was unresponsive to GCSF and required alternative CMV prophylaxis prior to day +100 and in those who developed CMV viremia. No other risk factors were found to be associated with 1-year survival or 1-year NRM.
- |||||||||| Cytovene (ganciclovir) / Roche, Kineret (anakinra) / SOBI
CYTOMEGALOVIRUS INDUCED ADULT ONSET STILL’S DISEASE AND FULMINANT MYOCARDITIS (Poster Hall_Hall C) - Jan 28, 2022 - Abstract #ACC2022ACC_6261;
The patient was found to be under-supported on dobutamine and milrinone with a CI of 1.7 L/min/m2, MVO2 Sat of 44%, CPO of 0.75 Watts and PAPi of 1.2...After multidisciplinary discussion, our patient was treated with methylprednisolone 1 g daily for three days followed by a a steroid taper and anakinra daily. Cardiologists treating acute myocarditis must maintain a high suspicion for the rare etiologies responsive to immunosuppression, like adult-onset Still’s disease, so that treatment is not delayed.
- |||||||||| Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Cytovene (ganciclovir) / Roche, Kineret (anakinra) / SOBI
ADULT-ONSET STILL'S DISEASE AND CARDIOMYOPATHY FOLLOWING COVID-19 INFECTION (Complex Clinical Cases Moderated Poster Theater 3_Hall C) - Jan 28, 2022 - Abstract #ACC2022ACC_4112;
By day three he required inotropic support with Dobutamine and Norepinephrine, and by day six required cannulation for ECMO...On day thirteen his treatment was complicated by a spike in his initially normal CMV levels, and Anakinra was held while IV Ganciclovir was given for ten days followed by oral Valganciclovir... We report the case of a young male who developed Adult-Onset Still’s Disease three weeks after his diagnosis of Covid-19, who developed cardiogenic shock requiring ECMO support and responded to treatment with Anakinra, whose course was complicated by CMV viremia.
- |||||||||| SUCCESSFUL CLEARANCE OF CYTOMEGALOVIRUS COLITIS IN ACUTE SEVERE ULCERATIVE COLITIS DURING INDUCTION OF OZANIMOD () - Jan 28, 2022 - Abstract #CCCongress2022CCCongress_378;
CASE REPORT A 21-year-old male with UC treated with tofacitinib presented with five days of diffuse abdominal pain and 10-12 episodes of bloody diarrhea per day with CRP 341mg/L (3000μg/g (<49μg/g)...He previously failed infliximab, adalimumab, ustekinumab, and vedolizumab...The patient refused colectomy and was started on IV ganciclovir 5mg/kg q12h while transitioning to prednisone 40mg/day...He remained on ganciclovir for three weeks then transitioned to oral valganciclovir 900mg BID...The improvement in clinical biomarkers of colitis and viral clearance suggest that ozanimod given with ganciclovir may be an exciting rescue therapy in these patients. Future studies will be needed to ascertain the rates of ozanimod response and CMV clearance in a larger patient cohort.
- |||||||||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Xeljanz (tofacitinib) / Pfizer
HIGH DOSE TOFACITINIB AS SALVAGE THERAPY IN STEROID REFRACTORY ACUTE SEVERE ULCERATIVE COLITIS FOLLOWING NON-RESPONSE TO INFLIXIMAB () - Jan 28, 2022 - Abstract #CCCongress2022CCCongress_374;
She was on the maximum 5-Aminosalicylic dose and could not tolerate azathioprine in the past...The third dose of Infliximab was postponed, and the patient received IV ganciclovir followed by oral therapy for two weeks duration...Our patient showed clinical and biochemical remission within three days. At three months follow up, the patient remained colectomy-free and was in sustained remission.
- |||||||||| temozolomide / Generic mfg.
Engineering suicide gene approaches to improve chemotherapeutic response in glioblastoma (In-Person Room (Virtual Room)) - Jan 28, 2022 - Abstract #ACSSp2022ACS_Sp_10299;
This presentation will describe our findings on the selectivity of these constructs for p38-dependent cell killing and the cooperativity of these novel suicide genes with temozolomide chemotherapy. More broadly, this work will demonstrate the potential utility of post-translational control of suicide gene activity as an alternative to transcriptional regulation.
- |||||||||| Vistide (cidofovir) / Gilead
Review, Journal: Current Drugs to Treat Infections with Herpes Simplex Viruses-1 and -2. (Pubmed Central) - Jan 26, 2022
While numerous experimental vaccines are under consideration, current intervention consists solely of antiviral chemotherapeutic agents. This review explores all of the clinically approved drugs used to prevent the worst sequelae of recurrent outbreaks by these viruses.
- |||||||||| ampicillin / Generic mfg., voriconazole / Generic mfg.
Review, Journal: Stability of Antimicrobials in Elastomeric Pumps: A Systematic Review. (Pubmed Central) - Jan 26, 2022
The information provided in this article should be considered in patient treatments within the OPAT setting. Further stability studies are needed to confirm the appropriate use of the antimicrobials included in this program to ensure optimal patient outcomes.
- |||||||||| Cytovene (ganciclovir) / Roche
Clinical, Journal: NUDT15-mediated hydrolysis limits the efficacy of anti-HCMV drug ganciclovir. (Pubmed Central) - Jan 21, 2022
More critically, GCV efficacy was potentiated in HCMV-infected cells following NUDT15 depletion by RNAi or inhibition by an in-house-developed, nanomolar NUDT15 inhibitor, TH8321, suggesting that pharmacological targeting of NUDT15 is a possible avenue to improve existing anti-HCMV regimens. Collectively, the data further implicate NUDT15 as a broad-spectrum metabolic regulator of nucleoside analog therapeutics, such as thiopurines and GCV.
- |||||||||| sirolimus / Generic mfg., cyclosporine / Generic mfg.
Conversion to sirolimus in kidney transplant patients: the main indications (Poster Area (Virtual)) - Jan 21, 2022 - Abstract #ISNWCN2022ISN_WCN_1373;
The aim is to minimize the side effects of calcineurin inhibitors and ensure better graft and patient survival. According to our study, neoplastic complications and calcineurin inhibitors toxicity are the main indications of conversion to Sirolimus in Tunisia.
|
